An open-label, long-term study examining the safety and tolerability of pregabalin in Japanese patients with central neuropathic pain.

ABSTRACT:

Purpose

Studies of pregabalin for the treatment of central neuropathic pain have been limited to double-blind trials of 4-17 weeks in duration. The purpose of this study was to assess the long-term safety and tolerability of pregabalin in Japanese patients with central neuropathic pain. The efficacy of pregabalin was also assessed as a secondary measure.

Patients and methods

This was a 53-week, multicenter, open-label trial of pregabalin (150-600 mg/day) in Japanese patients with central neuropathic pain due to spinal cord injury, multiple sclerosis, or cerebral stroke.

Results

A total of 103 patients received pregabalin (post-stroke =60; spinal cord injury =38; and multiple sclerosis =5). A majority of patients (87.4%) experienced one or more treatment-related advers

SUBMITTER: Onouchi K 

PROVIDER: S-EPMC4122555 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature